• Muscle-Derived BDNF and MMPs Regulate Early NMJ Formation

  2026-07-15

  This study uncovers how muscle-generated BDNF, spatially localized and proteolytically processed by furin and matrix metalloproteinases (MMPs), directs the initial assembly of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings reveal a mechanistic framework for activity-dependent synaptic development and offer actionable insights for modulating NMJ assembly in vitro and in vivo.

• Cdk5 Downregulation Mitigates Neuronal Ferroptosis via AMPK

  2026-07-15

  This study demonstrates that inhibiting Cdk5 in mouse models of ischemic stroke reduces hippocampal neuron ferroptosis by modulating the AMPK pathway and microglial polarization. The findings provide mechanistic insight into neuroinflammation and ferroptosis, supporting the development of targeted interventions for neuronal injury.

• Protease Inhibitor Cocktail EDTA-Free: Unveiling Molecular P

  2026-07-14

  Discover how the Protease Inhibitor Cocktail EDTA-Free (100X in DMSO) enables unparalleled protein integrity during extraction and advanced assay workflows. Gain new insights into inhibitor selection and molecular stability, grounded in recent nanobiotech research.

• AZD0156: ATM Kinase Inhibitor Workflows for DNA Repair Resea

  2026-07-14

  AZD0156 accelerates high-fidelity DNA damage response studies by providing potent, selective ATM kinase inhibition for cancer therapy research. This article guides researchers through robust experimental setups, advanced troubleshooting, and data-driven protocol optimization to unlock reproducible results.

• Cy3-UTP for RNA Labeling: Enhanced Imaging & Interaction Ass

  2026-07-13

  Cy3-UTP empowers researchers to generate photostable, high-sensitivity fluorescent RNA for advanced imaging and RNA-protein interaction studies. Its robust incorporation streamlines in vitro transcription workflows and delivers reproducible results ideal for kinetic and structural RNA biology assays.

• Atorvastatin: HMG-CoA Reductase Inhibitor in Advanced Resear

  2026-07-13

  Atorvastatin is not only an essential HMG-CoA reductase inhibitor for cholesterol metabolism research but also a validated tool for studying ferroptosis and vascular cell biology. This article provides actionable protocols, troubleshooting tips, and a translational outlook for Atorvastatin’s multifaceted roles in both cardiovascular and oncology models.

• 25-Hydroxycholesterol Drives AMPK-STAT6 Axis in Tumor Macrop

  2026-07-12

  Xiao et al. unveil a lysosome-centered mechanism in which 25-hydroxycholesterol (25HC) accumulates within tumor-associated macrophages (TAMs), activating AMPKα through a GPR155-mTORC1 complex and initiating STAT6-dependent immunosuppressive programming. These findings clarify metabolic reprogramming in TAMs and suggest new angles for therapeutic intervention in the tumor microenvironment.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Pract

  2026-07-10

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) provides broad-spectrum protection against endogenous proteases during protein extraction and sample preparation, especially in workflows sensitive to divalent cations such as kinase assays and phosphorylation studies. It should not be used where EDTA-based inhibition is required or in workflows incompatible with DMSO.

• AG-126: Deep Dive into ERK Pathway Modulation for ASD Models

  2026-07-09

  Explore how AG-126 (Tyrphostin AG-126) enables advanced in vitro and in vivo ERK pathway modulation for autism spectrum disorder research. This article delivers novel insights and evidence-driven guidance for leveraging AG-126 beyond current literature.

• H-89: Selective cAMP-Dependent Protein Kinase Inhibitor Insi

  2026-07-09

  H-89 is a potent cAMP-dependent protein kinase inhibitor used for dissecting cAMP-mediated signaling, with high selectivity and reproducible inhibition at nanomolar concentrations. It is instrumental in elucidating the cAMP–PKA axis in metabolic and osteogenic research. Protocol precision and correct interpretation are crucial due to its limited solubility and off-target effects at higher doses.

• MK 0893 (A3608): Reliable Glucagon Receptor Antagonist for L

  2026-07-08

  This in-depth article addresses reproducibility and workflow challenges in type 2 diabetes research, focusing on MK 0893 (SKU A3608) as a robust glucagon receptor antagonist. With scenario-driven guidance, it helps biomedical researchers optimize cAMP inhibition assays and animal models using validated, literature-backed protocols. Explore how MK 0893 from APExBIO supports sensitive, reliable results in both cell-based and in vivo studies.

• A23187, Free Acid: Precision Tools for Quantitative Calcium

  2026-07-08

  Explore how A23187, free acid enables precise, quantitative manipulation of intracellular calcium in advanced in vitro models. This article uniquely connects technical assay design with the evolving landscape of drug response evaluation, offering actionable guidance for researchers.

• Advancing Gene Regulation: Dual Luciferase Systems in Transl

  2026-07-07

  This thought-leadership article explores the transformative potential of Dual Luciferase Reporter Gene Systems in dissecting transcriptional regulation, with a focus on mechanistic insight, strategic experimental design, and translational relevance—anchored by emerging evidence in noncoding RNA and the cAMP/PKA/CREB pathway. Bridging mechanistic biology and workflow innovation, it positions the APExBIO Dual Luciferase Assay System as a tool enabling rigorous, high-throughput analysis for researchers seeking actionable pathways from bench to clinic.

• IBDV VP3 Protein Drives IRF7 Degradation to Enhance Viral Re

  2026-07-07

  This study reveals a novel mechanism by which infectious bursal disease virus (IBDV) undermines host antiviral defense: the viral VP3 protein directly interacts with and promotes proteasome-mediated degradation of interferon regulatory factor 7 (IRF7), suppressing type I interferon responses. These insights clarify how highly virulent IBDV strains exploit the ubiquitin-proteasome system to facilitate viral replication, informing future antiviral intervention strategies.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Pract

  2026-07-06

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted proteolysis during protein extraction, especially in workflows where chelation of metal ions would interfere with downstream assays. It is suitable for applications like phosphorylation analysis and Western blotting, but should be avoided where EDTA-mediated inhibition is required.

15827 records 1/1056 page Next 12345 下5页 Last page